Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Vesicoureteral Reflux : Article by

Quick Find
Authors & Editors
Introduction
Indications
Relevant Anatomy
Contraindications
Workup
Treatment
Complications
Outcome And Prognosis
Future And Controversies
Multimedia
References




Patient Education
Kidneys and Urinary System Center

Bladder Control Problems Overview

Bladder Control Problems Causes

Bladder Control Problems Symptoms

Bladder Control Problems Treatment




Author: Marc Cendron, MD, Associate Professor of Surgery, Harvard School of Medicine; Consulting Staff, Department of Urological Surgery, Children's Hospital Boston

Marc Cendron is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, European Society for Paediatric Urology, Johns Hopkins Medical and Surgical Association, New Hampshire Medical Society, Society for Fetal Urology, and Society for Pediatric Urology

Editors: Daniel B Rukstalis, MD, Director of Urological Services, Geisinger Medical Center, Geisinger Medical Group; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; J Stuart Wolf, Jr, MD, FACS, David A Bloom Professor of Urology, Director, Division of Minimally Invasive Urology, Department of Urology, University of Michigan Medical Center; William J Cromie, MD, MBA, President and Chief Executive Officer, Health Care, Capital District Physicians' Health Plan

Author and Editor Disclosure

Synonyms and related keywords: VUR, reflux nephropathy, retrograde transmission of urine from the urinary bladder up the ureter and into the kidneys, reflux, pyelonephritis, hypertension, progressive renal failure, ureteral reimplantation

Vesicoureteral reflux (VUR) is characterized by the retrograde flow of urine from the bladder to the kidneys. VUR may be associated with urinary tract infection (UTI), hydronephrosis, and abnormal kidney development (renal dysplasia). The relation of these conditions to VUR is discussed in this article.

Unrecognized VUR may, in conjunction with UTIs, lead to long-term effects on renal function and overall patient health. Some patients with VUR have an increased risk of developing pyelonephritis, hypertension, and progressive renal failure. However, VUR occurs with a spectrum of severity and thus may affect patients differently. Some individuals may have a genetic predisposition to renal injury. Determination of outcomes of VUR treatment should consider not only resolution of reflux over time but also resolution of UTIs and the overall health of the kidneys. The evaluation and management of VUR in children is currently undergoing reevaluation, as guidelines for treatment are being rewritten.

Early diagnosis and vigilant monitoring of patients with VUR are the cornerstones of management. A voiding cystourethrogram (VCUG) or radionuclear cystourethrogram (RNC) is used to confirm the diagnosis. A dimercaptosuccinic acid (DMSA) renal scan is used to reveal any renal abnormalities. Yearly monitoring with renal ultrasonography to evaluate renal growth and a cystogram (RNC or VCUG) should be performed until the reflux resolves or the reflux is surgically treated. Prophylactic antibiotics are prescribed to reduce the risk of bacterial infection of the bladder while reflux is present. Bladder management to ensure good lower urinary tract hygiene should be considered in children who have undergone toilet training.

History of the Procedure

Galen and Asclepiades described the valve action of the ureterovesical junction as early as the second century AD. In 1903, Sampson and Young described the functional flap-valve mechanism at the level of the ureterovesical junction, which is created by the oblique course of the ureter within the intramural portion of the bladder wall. In 1913, Legueu and Papin described a patient with hydronephrosis and hydroureter in whom urine was shown refluxing through a widely patent ureteral orifice.

In his report on cystography in 1914, Kretschmer demonstrated that reflux was present in 4 of the 11 children he studied. In 1929, Gruber noted that the incidence of VUR varied according to the length of the intravesical ureter and muscularity of the detrusor backing. Paquin reported that the tunnel length–to–ureteral diameter ratio should be approximately 5:1 to prevent reflux. In the mid-to-late 1950s, Hutch postulated the causal relationship between VUR and chronic pyelonephritis in a cohort of patients with spinal cord injury, and, in 1959, Hodson demonstrated that renal parenchymal scarring occurs more commonly in children with VUR and UTIs.

Ransley and Ridson confirmed the studies of Tanagho in 1975 by showing that reflux could be experimentally created in animals by modifying the ureterovesical junction; in subsequent studies, they were able to show the correlation between reflux, renal papilla anatomy, pyelonephritis, and renal injury. At the same time, Smellie and Normand performed long-term studies of patients with reflux; they documented the natural history of patients treated medically.1

At the same time, Paquin, Hutch, Lich and Gregoire, Daines and Hudson, Politano and Leadbetter, Glenn and Anderson, and Cohen developed and popularized various surgical techniques for treating VUR. The International Reflux Grading System was adopted in the 1980s, and the International Reflux Study compared medical approaches with surgical approaches to reflux. Finally, endoscopic treatment for reflux was introduced in the late 1980s. In recent years, Noe and colleagues showed a genetic predisposition for reflux. In addition, with the widespread use of antenatal ultrasonography, prenatal diagnosis of VUR has been made possible.

Problem

VUR is defined as retrograde regurgitation of urine from the urinary bladder up the ureter and into the collecting system of the kidneys. The International Reflux Grading system classifies VUR into 5 grades, depending on the degree of retrograde filling and dilation of the renal collecting system. This system is based on the radiographic appearance of the renal pelvis and calyces on a voiding cystogram, as follows:

  • Grade I: Urine backs up into the ureter only, and the renal pelvis appears healthy, with sharp calyces.
  • Grade II: Urine backs up into the ureter, renal pelvis, and calyces. The renal pelvis appears healthy and has sharp calyces.
  • Grade III: Urine backs up into the ureter and collecting system. The ureter and pelvis appear mildly dilated, and the calyces are mildly blunted.
  • Grade IV: Urine backs up into the ureter and collecting system. The ureter and pelvis appear moderately dilated, and the calyces are moderately blunted.
  • Grade V: Urine backs up into the ureter and collecting system. The pelvis severely dilates, the ureter appears tortuous, and the calyces are severely blunted.

Frequency

Historically, epidemiologic studies using VCUG in presumably healthy neonates, infants, and children reported that the incidence of VUR is less than 1% in healthy children (Politano, 1960; Lich, 1964). However, this figure is probably an underestimation because no large population studies have been performed to assess the true incidence of VUR; in addition, reflux is discovered in selected patients such as those who present with a hydronephrosis or UTI or who have a family history of VUR.

VUR occurs 10 times more often in white children than in black children, and children with red hair have a recognized an increased prevalence rate. VUR is more prevalent in male newborns, but females older than one year seem to be found to have VUR 5-6 times more often than males. The incidence decreases as patient age increases.

Children with UTIs have a much higher incidence of VUR (ie, 40-50%). Approximately 13,000 children younger than 17 years are hospitalized in the United States for treatment of pyelonephritis. UTIs account for more than 1.1 million physician office visits among children younger than 18 years, and about 25,000 visits to urologists are for evaluation and treatment of VUR.

Today, the incidence of prenatally diagnosed hydronephrosis caused by VUR ranges from 17-37% in the pediatric population, and approximately 20-30% of children with VUR present with renal lesions. The incidence of VUR in children and young adults with end-stage renal failure (chronic renal insufficiency [CRI]) that necessitates therapy (dialysis or transplantation) is about 8%; VUR represents the third most common etiology of CRI in children.

A definite genetic component exists with VUR, but the exact mode of inheritance remains unknown. Currently, researchers hypothesize that VUR is inherited dominantly with a variable penetrance. Up to 76% of index case patients (ie, patients with reflux) develop VUR in utero, and up to 34% of those patients with reflux have siblings that also are affected.

Etiology

  • Primary causes
    • Short or absent intravesical ureter
    • Absence of adequate detrusor backing
    • Lateral displacement of the ureteral orifice
    • Abnormal configuration of the ureteral orifice (eg, stadium, horse shoe, golf hole)
  • Secondary causes
    • Cystitis or UTI
    • Bladder outlet obstruction
    • Detrusor instability
    • Duplicated collecting system
    • Paraureteral (Hutch) diverticulum

Pathophysiology

When the ureter inserts into the trigone, the distal end of the ureter courses through the intramural portion of the bladder wall at an oblique angle. The intramural tunnel length–to–ureteral diameter ratio is 5:1 for a healthy nonrefluxing ureter. As the bladder fills with urine and the bladder wall distends and thins, the intramural portion of the ureter also stretches, thins out, and becomes compressed against the detrusor backing. This process allows a continual antegrade flow of urine from the ureter into the bladder but prevents retrograde transmission of urine from the bladder back up to the kidney; thus, a healthy intramural tunnel, within the bladder wall, functions as a flap-valve mechanism for the intramural ureter and prevents urinary reflux.

An abnormal intramural tunnel (ie, short tunnel) results in a malfunctioning flap-valve mechanism and VUR. When the intramural tunnel length is short, urine tends to reflux up the ureter and into the collecting system. Pacquin reports that refluxing ureters have an intramural tunnel length–to–ureteral diameter ratio of 1.4:1. To prevent reflux during ureteral reimplantation, the physician must obtain a minimum tunnel length–to–ureteral diameter ratio of 3:1.

The human kidney contains 2 types of renal papillae: simple (convex) papilla and compound (concave) papilla. Compound papillae predominate at the polar regions of the kidney whereas simple papillae are located at nonpolar regions. Approximately 66% of human papilla is convex and 33% is concave.

Intrarenal reflux or retrograde movement of urine from the renal pelvis into the renal parenchyma is a function of intrarenal papillary anatomy. Simple papillae possess oblique, slitlike, ductal orifices that close with increases in intrarenal pressure. Thus, simple papillae do not allow intrarenal reflux. However, compound papillae possess gaping orifices that are perpendicular to the papillary surface that remain open with increases in intrarenal pressure. These gaping orifices allow free intrarenal reflux.

Patients with uncorrected VUR may develop renal scarring and impaired renal growth. Renal scars often are present at initial diagnosis and usually develop during the first years of life. Persistent intrarenal reflux causes renal scarring and eventual reflux nephropathy. Reflux nephropathy leads to impaired renal function, hypertension, and proteinuria.

Two types of urine may enter the renal papillae: infected urine or sterile urine. Intrarenal reflux of infected urine appears to be primarily responsible for the renal damage. The presence of bacterial endotoxins (lipopolysaccharides) activates the host's immune response and a release of oxygen free radicals. The release of oxygen free radicals and proteolytic enzymes results in fibrosis and scarring of the affected renal parenchyma during the healing phase.

Initial scar formation at the infected polar region distorts local anatomy of the neighboring papillae and converts simple papillae into compound papillae. Compound papillae, in turn, perpetuate further intrarenal reflux and additional renal scarring. Thus, a potentially vicious cycle of events may occur after initial intrarenal introduction of infected urine. Compound papillae are most commonly found at the renal poles where renal scarring is most commonly observed. Renal scan (DMSA) reveals these lesions focally. Diffuse lesions on renal scan are felt to be due to the presence of renal dysplasia, which results from an abnormal development of kidney. It is seen in patients who have higher grades of reflux (IV and V) and who have never had any evidence of UTI or pyelonephritis. As described by Yeung, these kidneys may have very low or no function in 5% of girls and 78% of boys.

Intrarenal reflux of sterile urine (under normal intrapelvic pressures) has not been shown to produce clinically significant renal scars. It appears that when children with uncomplicated VUR are treated with chronic low-dose antibiotic prophylaxis to maintain sterile urine, the incidence of renal scarring is rare.1, 2 Thus, renal scarring only appears to occur in a setting of intrarenal reflux in combination with UTI. One exception to this statement is intrarenal reflux of sterile urine in the setting of abnormally high detrusor pressures.

Hodson et al completely obstructed the urethra of Sinclair miniature piglets and created an artificially high intravesical pressure that was transmitted to the renal pelvis. Intrarenal reflux of sterile urine in this highly pressurized system led to the formation of renal scars. Apparently (at least in animal model studies), sterile reflux may also produce scarring but only with high intravesical pressures (eg, infravesical outlet obstruction or poorly compliant neurogenic bladder).

Renal lesions are associated with higher grades of reflux. Pyelonephritic scarring may cause serious hypertension. Scarring related to VUR is one of the most common causes of childhood hypertension. Wallace reports that hypertension develops in 10% of children with unilateral scars and in 18.5% with bilateral scars. In adults with reflux nephropathy, 34% of those patients ultimately develop hypertension. Approximately 4% of children with VUR progress to end-stage renal failure. Renal units with low-grade reflux may grow normally, but high grades of reflux are associated with renal growth retardation.

Bladder outlet obstruction, a neurogenic condition, learned voiding abnormalities (eg, nonneurogenic neurogenic bladder, or Hinman syndrome), and gastrointestinal dysfunction may cause VUR. Unphysiologically elevated intravesical pressures are common with all of these abnormalities. Children with overactive bladders (eg, detrusor hyperreflexia, detrusor instability) generate a high intravesical pressure, which can exacerbate preexisting VUR or cause secondary VUR. These children empty their bladder relatively well, with minimal postvoid residual urine. Acquired voiding dysfunction (eg, Hinman syndrome [nonneurogenic neurogenic bladder]) produces functional bladder outlet obstruction from voluntary contraction of the external sphincter during urination. These children generate high intravesical pressure, develop detrusor instability, and have high postvoid residual urine volumes. Encopresis and constipation also are common.

Clinical

Clinical presentation may occur in the prenatal period, when transient dilatation of the upper urinary tract is noted in conjunction with bladder emptying when the examination is carry out later in gestation (>28 wk).

VUR may be diagnosed in a neonate who presents with respiratory distress, persistent vomiting, failure to thrive, renal failure, flank masses, and urinary ascites and may be subsequently diagnosed with severe UTI.

Older children may present with symptoms of UTI (eg, urgency, frequency, dysuria) and nocturnal and diurnal enuresis. Other constitutional symptoms include failure to thrive and gastrointestinal disturbances (eg, nausea, vomiting).



The goals of medical intervention are to allow normal renal growth, to prevent UTI and pyelonephritis, and to prevent renal failure. Initiate medical management for prepubertal children with grades I-III reflux and most children with grade IV reflux.

Relative indications for surgical management include grades IV and V reflux, persistent reflux despite medical therapy (beyond 3 y), breakthrough UTIs while on antibiotic prophylaxis, lack of renal growth, multiple drug allergies that preclude the use of prophylaxis, and parents/patient or physician desire to be free of antibiotic prophylaxis. Absolute indications for surgical management include medical noncompliance with medical therapy, breakthrough pyelonephritis, progressive renal scarring on antibiotic prophylaxis, and an associated ureterovesical junction abnormality.



The normal valve mechanism of the ureterovesical junction includes oblique insertion of the intramural ureter, adequate length of the intramural portion of the ureter, and strong detrusor support.

The ureter is composed of 3 muscle layers: inner longitudinal, middle circular, and outer longitudinal. The outer longitudinal layer is enveloped by ureteral adventitia. The inner longitudinal layer of smooth muscle passes through the ureteral hiatus, continues distally beyond the ureteral orifice into the trigone, and intertwines with the smooth muscle fibers of the contralateral ureter, forming the Bell muscle of the trigone and posterior urethra. The middle circular muscle fibers, outer longitudinal muscle fibers, and periureteral adventitia merge with the bladder wall in the upper part of the ureteral hiatus to form the Waldeyer sheath. This sheath attaches the extravesical portion of the ureter to the ureteral hiatus.



Ureteral reimplantation is contraindicated as a first-line therapy in those patients with secondary vesicoureteral reflux (VUR), which may arise as an inappropriate increase in detrusor filling pressure.

Causes of secondary reflux include chronic bladder outlet obstruction, neurologic disorders (eg, myelomeningocele, spinal cord injury), and overactive bladder. All of these disease processes lead to poor bladder compliance; therefore, treat detrusor dysfunction before performing a ureteral reimplantation. If the physician neglects the bladder and proceeds with ureteral implantation first, the risk of recurrent reflux is high, or, if the bladder wall is abnormally thickened, the risk of distal ureteral obstruction is greater after surgical treatment. Contraindications to surgery include detrusor instability or Hinman syndrome.



Lab Studies

  • Perform a urinalysis and urine culture in all neonates born with antenatal or postnatal hydronephrosis to rule out a UTI. More than 90% of newborns void within the first 24 hours.
  • The serum creatinine level of a neonate reflects that of maternal creatinine (ie, 1 mg/dL) in the first 24 hours of life; thus, repeat the serum creatinine assessment after at least 24 hours. The average serum creatinine level in a healthy neonate is approximately 0.4 mg/dL.
  • Obtain serum electrolytes in neonates with antenatal hydronephrosis from vesicoureteral reflux (VUR) because they may have dysplastic kidney on the affected side. Check for acidosis.

Imaging Studies

  • The recommended radiographic evaluation for VUR includes a VCUG, renal-bladder ultrasound, and nuclear renal scan (DMSA).
    • Perform a VCUG and renal-bladder ultrasound in any child with a documented UTI prior to age 5 years, any child with pyelonephritis, and any male child with a symptomatic UTI.
    • A renal-bladder ultrasound may be used to screen older children with UTI. If ultrasound findings are abnormal, conduct further workup studies with a VCUG to rule out VUR.
    • Suggest that siblings or offspring of index cases with known VUR undergo cystographic screening during the first few months of life, as they carry a 30% chance of concomitant VUR.
    • During the initial workup of a patient with suspected reflux, perform the standard VCUG, which provides clear anatomic detail and allows accurate grading of the reflux degree. By filling and emptying the bladder several times (cycling) with the catheter still in the bladder, as described by Lebowitz, the yield of identifying VUR is clearly enhanced. The conventional cystogram provides more anatomical accuracy than the nuclear cystograms; however, nuclear cystograms are advantageous (used widely to monitor VUR) because of lower radiation exposure and increased sensitivity. Physician also can use nuclear cystograms to screen family members of a patient with known reflux.
  • Voiding cystourethrogram/radionuclear cystourethrogram
    • Perform the VCUG while the patient is awake and include a voiding phase. Appearance of the urethra is important to determine if the child has some degree of voiding dysfunction or, in males, if the child has posterior urethral valves. VUR is graded based on appearance of contrast in the ureter and upper collecting system during the voiding phase of the cystogram. The VCUG also helps to evaluate the bony structures such as the lower spine and the pelvic architecture. It may also show whether the child has an excess of feces the colon.
    • In a neonate or small child, place a pediatric feeding tube rather than a Foley catheter in the urinary bladder. The Foley balloon may lead to a false diagnosis of a ureterocele or evoke an involuntary bladder spasm, making the test difficult.
    • After filling the bladder with contrast, remove the feeding tube and allow the child to void.
    • The voiding phase of the cystogram is considered the most important part of the test for assessing reflux. Perform the VCUG, rather than a nuclear cystogram, during the initial evaluation of a patient with suspected reflux; this provides good anatomic information about the lower urinary tract.
    • Allowing the bladder to fill and to empty several times (cycling) increases the sensitivity of the study.
  • Renal and bladder ultrasound
    • Obtain a renal ultrasound to evaluate the presence and degree of hydronephrosis. If hydronephrosis is present, inspect the ureters for dilation. In a female patient, a dilated ureter in the presence of hydronephrosis usually indicates VUR; however, hydronephrosis in a male infant with an undilated ureter implies ureteropelvic junction obstruction.
    • Evaluate the appearance of the renal parenchyma and size of the kidneys. Abnormal or dysplastic kidneys are smaller and appear brighter or more echogenic. Presence of the corticomedullary junction indicates a normal kidney.
    • Ultrasound is also a good modality to monitor kidney growth over time.
    • Evaluation of the bladder (prevoid and postvoid, measurement of bladder thickness) provides additional information about the lower urinary tract and bladder function. Bladder ultrasound helps to reveal bladder wall thickness, a dilated ureter, and the presence of a ureterocele or ectopic ureter. It also gives information about incomplete bladder emptying due to voiding dysfunction.
    • Compare renal size over time to assess renal growth.
    • Renal ultrasound has not been demonstrated to be a reliable modality for revealing renal lesions, but obvious renal scarring can be seen in more severe cases.
  • Nuclear renal scan
    • DMSA is considered the best nuclear agent for visualizing the cortical tissue, evaluating renal function, and revealing the presence of renal scars. To detect pyelonephritis and renal scarring associated with reflux, use the technetium Tc 99m–labeled DMSA renal scintigraphy. Pyelonephritis impairs renal tubular uptake of a radionuclide isotope, which causes cortical photon defects on the DMSA scan. Persistent photopenic defects on the DMSA scan represent renal scarring and irreversible renal damage.
    • The DMSA scan is used to confirm suspected pyelonephritis and to evaluate the effectiveness of VUR medical management. Patterns of abnormal radionuclide may also help to differentiate between renal lesions caused by infections (focal areas of low uptake, usually upper and lower poles of the kidney) from diffuse decreased uptake seen in renal dysplasia due to abnormal renal development.
    • The presence of photopenic areas within the kidney reflects a history of previous pyelonephritis.
    • Development of new photopenic areas within the renal cortex, especially in the polar regions, indicates new scar formation.
    • Diffuse decreased uptake of the radionuclide may indicate renal dysplasia.
    • Recently, several authors have advocated DMSA renal scan as the first study after a febrile UTI. Patients found to have renal lesions on DMSA were found to have a higher incidence of UTIs and VUR, thus preselecting patients who needed to undergo VCUG.
  • Follow-up imaging studies
    • Yearly ultrasonography helps monitor renal growth, detect of hydronephrosis, and evaluate bladder anatomy and voiding dynamics (filling and emptying).
    • Radionuclide cystogram every year to every 18 months helps monitor presence or resolution of VUR and helps to grade the amount of reflux. Compare with earlier studies to determine a trend towards resolution.
    • Obtain a nuclear cystogram during regular follow-up studies of a patient with known reflux.
    • Although not as anatomically accurate as the standard VCUG, a nuclear cystogram provides adequate information regarding the current status of VUR.
    • The main advantage of performing a nuclear cystogram is that it exposes the child to less radiation and may be more sensitive in revealing VUR.
    • Perform DMSA scan if the child develops evidence of pyelonephritis.

Other Tests

  • Urodynamics
    • Perform urodynamics in those patients with secondary VUR caused by lower urinary tract dysfunction.
    • Lower urinary tract dysfunction, which may cause secondary VUR, includes overactive bladder, spinal cord injury, and bladder outlet obstruction.

Diagnostic Procedures

  • Cystoscopy plays a limited role in VUR diagnosis. Conduct this study when the anatomy of the urethra, bladder, or upper tracts is incompletely defined with radiographic evaluation and when ureterocele is suspected.
    • Perform a video urodynamic evaluation with filling cystometrogram and a pressure-flow study with electromyography in any child with a suspected secondary cause of VUR.
    • Filling cystometrogram entails filling the bladder with a feeding tube and monitoring bladder pressures during filling and voiding. Normal bladder pressures should be less than 40 cm of water; however, the bladder pressure increase transiently to 60-80 cm of water during voiding.
    • Perform a filling cystometrogram to determine the presence of uninhibited detrusor contractions, bladder compliance, and detrusor leak point pressure, which are significant risk factors for VUR.

      High detrusor pressure and low urinary flow rate during a voiding cystometrogram indicates bladder outlet obstruction. This may develop from posterior urethral valves, detrusor sphincter dyssynergia, or Hinman syndrome in children. Bladder outlet obstruction is another secondary cause of VUR.



Medical therapy

Three therapeutic options are available to treat children with vesicoureteral reflux (VUR). They include medical treatment, surgical treatment, and surveillance (or observation).

The International Reflux Study has revealed that children can be managed nonsurgically with little risk of new or increased renal scarring, provided they are maintained infection free. The chance of spontaneous resolution of reflux is high in children younger than 5 years with grades I-III reflux and in children younger than 1 year (especially boys). Even higher grades of reflux (grades IV-V) may resolve spontaneously as long as they remain infection free.

Thus, medical management philosophy is based on the knowledge that low-grade reflux resolves spontaneously and sterile reflux does not damage the kidney. The medical management involves administering long-term suppressive antibiotics, correcting the underlying voiding dysfunction (if present), and conducting yearly follow-up radiographic studies (eg, VCUG, nuclear cystogram, DMSA scan) at regular intervals.

In 1997, the American Urological Association published a set of guidelines for the management of VUR in children that still serves as a good resource for patients, parents, and physicians.3 These guidelines are now 10 years old and are in the process of being rewritten.

The Pediatric Vesicoureteral Reflux Guidelines Panel has made the following recommendations for children with VUR:

Indications for antibiotic prophylaxis

  • Children without renal scarring at diagnosis
    • Diagnosis made in infancy: All patients diagnosed at infancy (ie, <1 y) with grades I-V reflux should be treated initially with continuous prophylactic antibiotics.
    • Diagnosis made in children aged 1-5 years: When unilateral and/or bilateral grades I-IV reflux or unilateral grades III-V reflux are diagnosed in children aged 1-5 years, they should be treated initially with continuous prophylactic antibiotics.
    • Diagnosis made in children aged 6-10 years: Children diagnosed at age 6-10 years with unilateral and/or bilateral grades I-II reflux and unilateral grades III-IV reflux should be treated initially with continuous antibiotic prophylaxis. However, some are advocating not treating patients with grade I or II VUR, as most of these patients are at low risk for UTIs and pyelonephritis provided they have no voiding dysfunction or constipation.
  • Children with renal scarring at diagnosis
    • Diagnosis made in infancy: Infants (ie, <1 y) with scarring at diagnosis and grades I-V reflux should be treated initially with continuous antibiotic prophylaxis.
    • Diagnosis made in children aged 1-5 years: Antibiotic prophylaxis is the preferred option for preschool-aged children (ie, 1-5 y) with renal scarring at diagnosis, unilateral and/or bilateral grades I-II reflux, unilateral grades III-IV reflux, and bilateral grades III-IV reflux.
    • Diagnosis made in children aged 6-10 years: In children diagnosed at age 6-10 years with renal scarring and unilateral and/or bilateral grades I-II reflux or unilateral grades III-IV reflux, antibiotic therapy is the preferred treatment option.

Correcting the voiding dysfunction nonsurgically

  • Adjunctive measures for a bladder regimen include behavior modification protocol to ensure that the child empties his/her bladder completely at regular intervals (every 3 h), adequate hydration, and constipation prevention.
  • Timed voiding with or without biofeedback, a regular bowel regimen, and intermittent catheterization are the cornerstones to treating a patient with dysfunctional voiding caused by the Hinman syndrome.
  • Treat children with detrusor instability by administering anticholinergic medications, monitoring fluid intake, and observing timed voiding. Ensure that the anticholinergic therapy does not exacerbate preexisting constipation.
  • Spontaneous resolution rates decrease as patient age increases and with higher grades of reflux. Consider recommending surgical intervention in children with reflux that has persisted for more than 3 years with no improvement in the grade of reflux if it grade II or greater.
  • Hydronephrosis observed on a prenatal ultrasound may be the first indication of VUR. Provide these infants with antibiotic prophylaxis (ie, amoxicillin) and obtain a VCUG within the first month after birth. At approximately 4 weeks, obtain a nuclear renal scan (ie, DMSA) if high grade (IV or V) is found.
  • Correct any serum electrolyte abnormalities resulting from a malfunctioning kidney.

Medications

Continuous antibacterial prophylaxis decreases the incidence of pyelonephritis and subsequent renal scarring for low-to-moderate grades of reflux; therefore, nonsurgical management is appropriate for mild-to-moderate VUR (ie, grades I-IV) in the absence of breakthrough infections or anatomic abnormalities, as previously discussed.

Drug Category: Antibiotics -- Therapy must cover all likely pathogens in the context of this clinical setting.

Drug Name - Trimethoprim-sulfamethoxazole (Bactrim, Bactrim DS, Septra, Septra DS) -- Effective antibiotic used to treat uncomplicated UTIs and prevent recurrent infections. Trimethoprim inhibits the enzyme dihydrofolate reductase to block the production of tetrahydrofolic acid from dihydrofolic acid. It can be used alone (without sulfa) and is available in a liquid form. Trimethoprim (Primsol) can be used in patients with a sulfa allergy. Sulfamethoxazole competes with paraaminobenzoic acid (PABA), important in folate metabolism, to inhibit bacterial synthesis of dihydrofolic acid.
In children <3 mo, amoxicillin is preferred.
Double-suppressive regimens of TMP-SMX every am and nitrofurantoin every pm may be effective when single-agent prophylaxis fails.
Adult Dose - 5-10 mg/kg/d PO
Pediatric Dose - <3 months: Not recommended
>3 months: 5-10 kg/d PO hs in toilet-trained children
Contraindications - Documented hypersensitivity; megaloblastic anemia due to folate deficiency
Interactions - May interfere with folic acid metabolism; increased risk of thrombocytopenia with purpura in patients taking thiazides and other diuretics; may prolong prothrombin time in patients taking coumadin; may increase half-life of phenytoin; may increase bioavailability of methotrexate; may increase risk of nephrotoxicity in patients taking cyclosporin; may increase digoxin levels, especially in elderly patients; indomethacin may increase blood levels of sulfamethoxazole; risk of megaloblastic anemia if used with pyrimethamine; may decrease efficacy of tricyclic antidepressants; may potentiate effects of oral hypoglycemic agents; one case of toxic delirium reported when used with amantadine
Pregnancy - C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions - Potential teratogen, may be used in pregnancy only if the potential benefit justifies the potential risk to the fetus; do not administer to neonates because they will develop kernicterus; monitor children, because they are known to bruise easily; during long-term antibiotic therapy, conduct ongoing follow-up studies with a periodic radiologic evaluation until spontaneous resolution of VUR is confirmed  
 
Drug Name - Nitrofurantoin (Furadantin, Macrobid, Macrodantin) -- An antibiotic specific for uncomplicated lower UTIs. Does not alter gastrointestinal bacterial flora and achieves high concentration in urine. Not indicated for use in pyelonephritis or perinephric abscess.
In children <3 mo, amoxicillin is preferred.
Adult Dose - 5-10 mg/kg/d PO
Pediatric Dose - <3 months: Not recommended
>3 months: 1-2 mg/kg/d PO hs
Contraindications - Documented hypersensitivity; renal insufficiency ( <60 mL/min creatinine clearance), anuria or oliguria
Interactions - Antacids containing magnesium trisilicate and uricosurics (probenecid, sulfinpyrazone) reduce nitrofurantoin excretion, increasing toxicity and decreasing efficacy of nitrofurantoin; may cause false-positive findings on urine glucose tests
Pregnancy - B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions - Potential teratogen, may be used in pregnancy only if clearly needed; do not administer to children with G6PD deficiency because the risk for hemolytic anemia develops; long-term treatment is associated with rare cases of pulmonary fibrosis  
 
Drug Name - Amoxicillin (Amoxil, Biomox, Trimox) -- A semisynthetic penicillin derivative that has broad-spectrum antibiotic activity against gram-positive and gram-negative bacteria (beta-lactamase negative). This is an effective antibiotic for treatment of uncomplicated or recurrent cystitis and also may be used as a long-term suppressive agent to prevent recurrent cystitis. However, rates of microbial resistance to amoxicillin have been steadily increasing over the last 20 y.
Adult Dose - 250-500 mg PO tid or 500-875 mg PO bid
Pediatric Dose - 5 mg/kg/d PO
Contraindications - Documented hypersensitivity; penicillin or cephalosporin allergy
Interactions - Concurrent use of probenecid may increase blood levels of amoxicillin; chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with antibacterial effects of penicillin; may cause false-positive results on urine glucose tests
Pregnancy - B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions - Poorly absorbed during labor; pseudomembranous colitis is reported; adjust dose in renal impairment; may enhance chance of candidiasis; chewable tablets may contain phenylalanine

Drug Category: Anticholinergics -- These agents are bladder relaxant medications that control detrusor overactivity. Detrusor overactivity is a common secondary cause of VUR. Secondary causes of reflux from poor bladder compliance may be effectively treated with proper use of anticholinergic agents.

Drug Name
- Oxybutynin (Ditropan) -- Inhibits action of acetylcholine on smooth muscle and has direct antispasmodic effect on smooth muscles, which in turn cause bladder capacity to increase and uninhibited contractions to decrease.
Adult Dose - Ditropan: 5 mg PO bid/tid
Ditropan XL: 5-30 mg PO qd
Pediatric Dose - Ditropan: 1-5 mg PO bid/tid
Ditropan XL: Not established
Contraindications - Documented hypersensitivity; glaucoma; partial or complete GI obstruction; chronic constipation; myasthenia gravis; ulcerative colitis; toxic megacolon
Interactions - May alter absorption of other drugs due to impaired GI motility; CNS effects increase when administered concurrently with other CNS depressants
Pregnancy - B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions - Use Ditropan XL with caution in patients with hepatic or renal impairment, gastrointestinal motility disorders, or GERD; caution in urinary tract obstruction, reflux esophagitis, and heart disease  
 
Drug Name - Tolterodine tartrate (Detrol, Detrol LA) -- Competitive muscarinic receptor antagonist for overactive bladder. However, differs from other anticholinergic types in that it has selectivity for urinary bladder over salivary glands. Exhibits a high specificity for muscarinic receptors. Has minimal activity or affinity for other neurotransmitter receptors and other potential targets, such as calcium channels.
Adult Dose - Detrol: 1-2 mg PO bid
Detrol LA: 2-4 mg PO qd; adjust dose according to individual response and tolerability
Pediatric Dose - Not established
Contraindications - Documented hypersensitivity; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma
Interactions - Patients being treated with macrolide antibiotics or antifungal agents should not receive doses of tolterodine higher than 1 mg bid
Pregnancy - C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions - Do not administer doses >1 mg bid to patients with significantly reduced hepatic function; caution in renal impairment

Surgical therapy

The philosophy of surgical management is based on the knowledge that high-grade reflux and persistent reflux in adolescents is not likely to resolve with continued medical therapy, especially in grade III reflux or greater. Another consideration in opting for surgical reflux management is the effect of repeated testing on patients and parents. In addition, lack of compliance with medical treatment may also dictate a surgical approach.

Surgical therapy options include open surgical procedures and endoscopic injection of a bulking agent.

Indications for surgery

  • Children without scarring at diagnosis
    • Diagnosis made in infancy 
      • In patients diagnosed in infancy (ie, <1 y), consensus is lacking regarding the role of continued antibiotic therapy versus surgery for patients with persistent grades I-II reflux after a period of antibiotic prophylaxis.
      • However, surgical repair may be recommended in patients with persistent unilateral grades IV-V reflux or bilateral grades III-V reflux after a period of antibiotic therapy should the parents prefer definitive therapy over watchful management while receiving antibiotic prophylaxis.
    • Diagnosis made in children aged 1-5 years 
      • In patients diagnosed at age 1-5 years, continuous antibiotic prophylaxis is the preferred option as an initial therapy for patients with unilateral grade V reflux; however, surgical repair is a reasonable alternative for grades IV and V of reflux.
      • In patients with bilateral grade V reflux, surgical repair is recommended.
      • Consensus is lacking regarding the role of continued antibiotics versus surgery in children with persistent grades I-II reflux after appropriate suppressive antibiotic therapy.
      • However, surgery is recommended for children with persistent grades III-V reflux in whom antibiotic therapy has not kept them infection-free.
      • Endoscopic treatment may be recommended in children with grade III to IV who have not shown any improvement in the reflux grade, who do not wish to receive further antibiotics, or who have had UTI.
    • Diagnosis made in children aged 6-10 years 
      • In patients diagnosed with bilateral grades III-IV reflux at age 6-10 years, surgical repair is the preferred option, although continuous antibiotics is a reasonable alternative.
      • Patients with grade V reflux should undergo surgical repair. In patients with persistent grades I-II reflux after a period of antibiotic prophylaxis, consensus is lacking regarding the role of continued antibiotics versus surgery.
      • However, surgery is an option for persistent reflux in children with grades III-IV reflux in whom initial antibiotic therapy has failed. They can either undergo open surgical or endoscopic treatment.
  • Children with scarring at diagnosis
    • Diagnosis made in infancy 
      • In children diagnosed in infancy (ie, <1 y) with grade V reflux and scarring, continuous antibiotic prophylaxis is the preferred option as an initial treatment; primary surgical repair is a reasonable alternative.
      • If the kidney is noted to have poor function (<15% on DMSA scan) consider removing the kidney and the ureter.
      • Consensus is lacking regarding the role of continued antibiotics versus surgery in patients with persistent grades I-II reflux after a period of antibiotic prophylaxis. These patients may be candidates for endoscopic treatment.
      • In boys with persistent unilateral grades III-IV reflux, surgical repair is the preferred option. In addition, boys with persistent bilateral grades III-IV reflux, girls with persistent unilateral and/or bilateral grades III-IV reflux, and any children with persistent grade V reflux should undergo surgical repair with an option for endoscopic treatment in grades II-IV.
    • Diagnosis made in children aged 1-5 years 
      • In children diagnosed at age 1-5 years with bilateral grades III-IV reflux and renal scars, antibiotic therapy is the preferred option; however, surgical repair is a reasonable alternative.
      • Patients with unilateral and/or bilateral grade V disease and scarring should undergo surgical repair as initial treatment or nephroureterectomy if the kidney has been shown to have little or no function on DMSA scan.
      • Consensus is lacking regarding the role of continued antibiotics versus surgery for patients with persistent grades I-II reflux after a period of antibiotic prophylaxis.
      • Girls with persistent unilateral and/or bilateral grades III-IV reflux and boys with persistent bilateral grades III-IV reflux should undergo surgical repair, either open or endoscopic.
      • Surgery is also an option for boys with persistent unilateral grades III-IV reflux.
      • For patients with persistent grade V reflux who have not undergone surgery as initial treatment, surgical repair is recommended.
    • Diagnosis made in children aged 6-10 years 
      • Patients diagnosed with bilateral grades III-IV reflux or grade V reflux at age 6-10 years can undergo surgical repair as initial treatment.
      • Consensus is lacking regarding the role of continued antibiotics versus surgery for patients who have persistent grades I-II reflux after a period of prophylaxis.
      • Patients with persistent unilateral grades III-IV reflux who have not undergone surgery as initial treatment should be offered either open surgical repair or endoscopic treatment.

Ureteral reimplantation

Surgery (ureteral reimplantation) is the definitive method of correcting primary reflux, especially in the setting of anatomic abnormalities. Surgical principles of successful reimplantation include (1) creating a long submucosal tunnel to provide a 5:1 tunnel-to-diameter ratio, (2) providing good detrusor muscle backing, (3) avoiding ureteric kinking, and (4) creating a tunnel in the fixed area of the bladder.

Standard antireflux ureteral reimplantation procedures include the transtrigonal (Cohen), intravesical (Leadbetter-Politano), and extravesical detrusorrhaphy techniques. The common goal of these operations is to prevent VUR by creating an effective flap-valve mechanism at the ureterovesical junction.

Potential complications due to ureteral reimplantation of the ureters include bleeding in the retroperitoneal space, infections, ureteral obstruction, injury to adjacent organs, and persistence of the reflux. These occur in less than 1% of cases.

Interestingly, surgical correction of VUR has not been demonstrated to decrease the frequency of recurrent UTIs. Most of these infections occur in the lower tract, thereby indicating that the risk to the kidneys may have been reduced by preventing ascent of the bacteria to the upper urinary tract. The antireflux does not completely prevent pyelonephritis, as a small percentage of patients who have undergone antireflux surgery represent with pyelonephritis. These infections may be due to the host predisposition to infection rather than to anatomic factors.

Endoscopic treatment

Puri and O'Donnel popularized endoscopic treatment of reflux in the 1980s. The principle of the procedure is to inject, under cystoscopic guidance, a biocompatible bulking agent underneath the intravesical portion of the ureter in a submucosal location. The bulking agent elevates the ureteral orifice and distal ureter in such a way that the lumen is narrowed, preventing regurgitation of urine up the ureter but still allowing its antegrade flow. The procedure is performed with general anesthesia on an outpatient basis.

Several bulking agents have been evaluated. These include polytetrafluoroethylene (PTFE or Teflon), collagen, autologous fat, polydimethylsiloxane, silicone, chondrocytes and, more recently, a solution of dextranomer/hyaluronic acid (Deflux). Concerns about PTFE particle migration have precluded FDA approval for use in children.

Other compounds such as collagen and chondrocytes have not stood the test of time. Recently, dextranomer/hyaluronic was FDA approved for the treatment of VUR in children. Initial clinical trial showed that this method was effective in treating reflux. A recent meta-analysis by Elder et al demonstrates that, after one treatment, the resolution rate of reflux per ureter for grades I and II was 78.5%; grade III, 72%; grade IV, 63%; and grade V, 51%, all compounds being considered.4 Retreatment can be performed up to 3 times, bringing the aggregate rate of resolution to 85%. Improvement in injection techniques may yield better results. Unfortunately, long-term studies have not yet been carried out to assess the longevity of the material and its effectiveness over time in curing reflux. Complications are rare with the procedure, with transient ureteral obstruction and UTIs being the most commonly reported.

Preoperative details

  • Prior to antireflux surgery, obtain an informed consent.
  • Discuss potential risks and complications (eg, persistent reflux, ureteral stricture, development of de novo contralateral reflux, ureteral obstruction).
  • Document the absence of UTI prior to surgery. If a UTI is noted, surgery should postponed until the infection is eradicated.
  • If infection is present, eradicate it by administering preoperative broad-spectrum intravenous antibiotics.

Intraoperative details

  • After satisfactory induction of a general anesthetic, place the patient in a supine fashion, with legs in the frog-leg position.
  • Sterilize the patient with povidone-iodine soap from umbilicus to mid thigh and drape the patient so that that the urethra may be accessed with the lower abdomen in the center of the field.
  • Create a low transverse incision approximately 1 cm above the symphysis pubis.
  • Carry the incision down to the rectus abdominis muscle.
  • Divide the rectus fascia in the midline and mobilize it from the underlying rectus muscles.
  • Bluntly separate the rectus and pyramidalis muscles at the midline, thus exposing the prevesical space and bladder.
  • Carefully dissect the peritoneum off the dome of the bladder and develop the lateral perivesical space.
  • At this point, further dissection varies with the type of ureteral reimplantation.

Extravesical (Lich-Gregoir) reimplantation

  • Fully mobilize the bladder from the space of Retzius and lateral pelvic sidewalls with a gentle blunt dissection.
  • Insert a self-retaining abdominal wall retractor.
  • Identify the ipsilateral obliterated hypogastric artery.
  • Locate the ureter medial to the pelvic portion of the obliterated hypogastric artery. Free the refluxing ureter down to its insertion into the bladder wall.
  • Use electrocautery to incise the bladder muscle down to mucosa for a distance of 3-5 cm from the ureterovesical junction. Undermine the lateral edges of the incision to create a trough that forms a new bed for the ureter.
  • Carefully lay the ureter in the newly created trough. Then, close the detrusor muscle over the ureter with interrupted 2-0 or 3-0 absorbable sutures.
  • Consider leaving a closed-suction drain in the prevesical space and leave the Foley catheter indwelling.
  • Remove the Foley catheter 24-48 hours after surgery, and remove the drain 24 hours later.

Extravesical detrusorrhaphy (Hodgson-Zaontz)

  • Following the initial dissection, extravesically dissect out the ureter down to the ureterovesical junction. Dissect the terminal ureter free from perivesical tissues but leave its attachment to the bladder mucosa intact.
  • Perform electrocautery to incise the bladder muscle down to the mucosa for a 5-cm arc around the ureterovesical junction. Undermine the lateral edges of the incision to create a trough that will form a new bed for the ureter.
  • Telescope the ureter into the bladder so it courses within a long subepithelial tunnel. Neither a ureteral stent nor a perivesical drain is needed.
  • Leave the indwelling Foley catheter overnight.

Intravesical reimplantation

  • Following the initial dissection, open the bladder in the midline using electrocautery.
  • Place a self-retaining retractor.
  • Cannulize the refluxing ureter with a 3.5-5F feeding tube. Secure the tube to the distal ureter with a traction suture.
  • Create a circumferential incision around the ureteral orifice. With careful dissection, the distal ureter is completely freed from the intramural portion of the bladder.
  • Then, fashion a new submucosal tunnel 4-5 times the diameter of the ureter.
  • The nomenclature for the different types of intravesical reimplantation vary with the location of the new ureteral hiatus (where the ureter enters the bladder wall) and the course of the ureter as follows:
    • The Politano-Leadbetter repair creates a new ureteral hiatus more cephalad to the original ureteral hiatus.
    • The Glenn-Anderson repair creates a new ureteral hiatus more distal to the original hiatus.
    • The Cohen repair creates a ureteral tunnel that is directed laterally across the trigone (transtrigonal) towards the contralateral side.
  • After reimplanting the ureter with adequate detrusor backing, a feeding tube may be left in the ureter to prevent ureteral obstruction from postsurgical edema. Currently, a trend has emerged for not leaving a stent in the ureter unless transient obstruction is a concern.
  • The feeding tube may be brought out through the urethra in females or through a separate stab incision in the lower quadrant of the abdomen.
  • Drain the bladder with a Foley catheter.
  • Close the bladder in 2 layers with running 4-0 and 3-0 absorbable sutures.

Endoscopic treatment

  • After induction of satisfactory general anesthesia, the patient is placed in the relaxed lithotomy position and the genitalia and perineum are prepared in a sterile manner.
  • Cystourethroscopy is carried out using a deflected lens scope. The bladder and ureteral orifices are inspected.
  • An injection needle is then advanced, bevel up to the ureteral orifice. The orifice is kept open by hydrodistending it with irrigation fluid; the needle is then advanced into the ureter. A submucosal puncture is made and the bulking is slowly injected.
  • As it spreads in the submucosal space, the material elevates the intravesical ureter, and the orifice acquires an inverted smile appearance. The needle is slowly withdrawn after between 0.5 and 2 mL of material has been injected.
  • The bladder is emptied and reinspected. Any bleeding vessels may be cauterized with a Bugbee electrode.

Postoperative details

  • Continue intravenous antibiotic administration until the patient is tolerating a diet.
  • Manage bladder spasms with anticholinergics or belladonna and opium (B&O) suppositories. Valium can also be helpful for severe bladder spasms.
  • Discharge the patient within 1-2 days.
  • Continue postoperative antibiotic prophylaxis until radiographic findings confirm complete resolution of reflux.

Follow-up

  • Obtain a postoperative renal ultrasound in 1 month.
  • Perform a nuclear cystogram in 3 months if endoscopic treatment has been performed. The current trend is to forego the follow-up cystogram, as 98% of findings are negative after an open surgical repair.
  • Conduct an interval renal ultrasound annually for 3 years.
  • During the scheduled follow-up studies, monitor patient blood pressure, renal function, and urinalysis.
  • After confirming resolution of reflux, discontinue antibiotic prophylaxis.
  • For excellent patient education resources, visit eMedicine's Kidneys and Urinary System Center. Also, see eMedicine's patient education article Bladder Control Problems.



Persistent, transient, contralateral reflux

Persistent reflux of the reimplanted ureter and development of de novo reflux of the contralateral side usually are temporary and resolve spontaneously. Transient postoperative reflux usually is caused by detrusor instability of the healing bladder.

Persistent reflux of the ipsilateral ureter in the absence of secondary causes (eg, poorly compliant bladder) is usually caused by a technical error. Some technical problems associated with ureteral reimplantation include inadequate ureteral mobilization, short intramural tunnel, inadequate anchoring of the ureter, and inappropriate placement of the ureteral orifice. Reoperate in this setting or consider endoscopic treatment if the reflux is grade III or less.

Most contralateral reflux is caused by recurrent or previously undiagnosed reflux that is now evident in the absence of the pop-off valve, which was previously provided by the refluxing ureter. Physicians can manage most of these patients conservatively, and patient symptoms usually subside spontaneously.

If a patient experiences persistent or severe vesicoureteral reflux (VUR) following repair, perform a thorough workup, including urodynamics, imaging, and cystoscopy. Correct failed repairs or poor tunnels with repeat repair.

Postoperative ureteral obstruction

Ureteral edema, intraureteral blood clots or mucous, bladder spasms, or submucosal bladder hematoma may cause acute ureteral obstruction in the early postoperative period. Ureteral angulation or ureteral hiatus that is made too tight also may cause acute ureteral obstruction. Ischemia, an incorrect tunnel construction, or an incorrect tunnel position may cause chronic postoperative ureteral obstruction.

When diagnosing ureteral obstruction, conduct a renal ultrasound, intravenous pyelogram, or nuclear renography to confirm diagnosis. Most postoperative ureteral obstructions resolve spontaneously; however, temporary ureteral stenting may be necessary. Nephrostomy tube placement rarely is required. Ureteroscopic dilation and stent placement may correct mild obstruction or stenosis. Percutaneous placement of a nephrostomy tune may be necessary if transvesical approach is not achievable.

Repeat reimplantation may be required for more severe cases. Ensure that the ureter is transected outside the bladder during reoperation and consider using a psoas hitch or transureteroureterostomy because of its inadequate length.

Bladder diverticula may complicate reimplantation surgery either at the site of bladder closure or at the reimplantation site. This may necessitate reoperation if the diverticula drains poorly or is associated with reflux or an obstruction.

Urinary extravasation indicates incomplete healing of the bladder or implanted ureterovesical junction. Prolonged catheterization or stenting is warranted.

Hematuria

Gross hematuria after ureteral reimplantation is common. Persistent bleeding or clots indicate inadequate hemostasis at the time of operation. Hematuria often is self-limited and does not require operative intervention; however, continue prolonged catheterization until hematuria resolves. Patients rarely need transurethral fulguration or reoperation.

Urosepsis

Urosepsis develops from an untreated UTI or ureteral obstruction. To prevent sepsis, clear preoperative urine cultures of infection. If urosepsis develops from ureteral obstruction, relieve the obstruction promptly and institute the appropriate antibiotics.

Anuria

Anuria is rare and may indicate dehydration or bilateral ureteral obstruction. Provide therapy via intravenous fluid challenges and furosemide. Check ureteral catheters for patency. If ureteral catheters were not used, obtain upper tract imaging studies to rule out bilateral ureteral obstruction. Manage bilateral ureteral obstruction with either bilateral retrograde stents or percutaneous nephrostomy tubes.



The success rate of ureteral reimplantation is higher than 95% when performed by experienced surgeons. Incidence of pyelonephritis significantly decreases after surgical repair compared to medical management with long-term antibiotic therapy; however, incidence of cystitis or renal scarring is the same following both medical and surgical management of vesicoureteral reflux (VUR).

Endoscopic treatment carries a lower success rate then open surgical treatment but offers and alternative to either medical treatment or open surgical treatment. Unfortunately, to date, no long-term, multi-institutional study has been carried out the evaluate and compare the three management options. Outcome measures should consider not only resolution of reflux but also long-term renal health and rate of UTIs.



Whether minimally invasive therapy using periureteral-bulking agents will be the future of vesicoureteral reflux (VUR) remains to be determined.

Several investigators have reported that laparoscopic surgery may be a possible alternative to open ureteral reimplantation. Animal and human studies have demonstrated the feasibility of the technique but have not shown a significant improvement over currently available techniques.

Current research efforts are directed toward better understanding of the genetics of VUR, refining the diagnostic criteria in order to better identify patients who seem to be at increased risks for renal damage, and determining who would benefit most from definitive therapy. Finding molecular markers associated with renal injury will also help to guide the treatment of patients with VUR.



Media file 1:  A voiding cystourethrogram (VCUG) of a patient with grade III vesicoureteral reflux (VUR). Note that the contrast flows up the ureter and into the renal pelvis. The calyces are sharp, and no evidence of hydronephrosis exists.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  X-RAY

Media file 2:  This is an example of grade V vesicoureteral reflux (VUR). Note the dilated renal pelvis and calyces. The ureter also is dilated and tortuous.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  X-RAY

Media file 3:  This is bilateral vesicoureteral reflux (VUR) with paraurethral (Hutch) diverticulum.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  X-RAY

Media file 4:  Vesicoureteral reflux (VUR). Nuclear cystogram showing reflux of radioisotope into left collecting system.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  X-RAY

Media file 5:  A dimercaptosuccinic acid (DMSA) scan in vesicoureteral reflux (VUR). Photopenic areas of the left kidney indicate renal scarring.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  X-RAY



  1. Smellie JM, Normand C. Reflux nephropathy in childhood. In: Hodson CJ, Kincaid-Smith P, eds. Reflux Nephropathy. New York, NY: Masson Publishing USA; 1979:14-20.
  2. Lenaghan D, Whitaker JG, Jensen F. The natural history of reflux and long-term effects of reflux on the kidney. J Urol. Jun 1976;115(6):728-30. [Medline].
  3. The American Urological Association Pediatric Vesicoureteral Reflux Guidelines Panel. Caring for Children With Primary Vesicoureteral Reflux. American Urological Association. Available at http://www.auanet.org/content/guidelines/patient_guides/PedRefluxptguide.pdf.
  4. Elder JS, Diaz M, Caldamone AA, Cendron M, Greenfield S, Hurwitz R. Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. J Urol. Feb 2006;175(2):716-22. [Medline].
  5. Arant BS Jr. Vesicoureteral reflux and evidence-based management. J Pediatr. Nov 2001;139(5):620-1. [Medline].
  6. Beetz R, Mannhardt W, Fisch M, Stein R, Thüroff JW. Long-term followup of 158 young adults surgically treated for vesicoureteral reflux in childhood: the ongoing risk of urinary tract infections. J Urol. Aug 2002;168(2):704-7; discussion 707. [Medline].
  7. Bouachrine H, Lemelle JL, Didier F. A follow-up study of pre-natally detected primary vesico-ureteric reflux: a review of 61 patients. Br J Urol. Dec 1996;78(6):936-9. [Medline].
  8. Canning DA. Five-year study of medical or surgical treatment in children with severe vesico-ureteral reflux. Dimercaptosuccinic acid findings. J Urol. Jan 2000;163(1):380. [Medline].
  9. Choi H, Oh SJ, So Y. No further development of renal scarring after antireflux surgery in children with primary vesicoureteral reflux: review of the results of 99mtechnetium dimercapto-succinic acid renal scan. J Urol. Sep 1999;162(3 Pt 2):1189-92. [Medline].
  10. Cooper CS, Chung BI, Kirsch AJ. The outcome of stopping prophylactic antibiotics in older children with vesicoureteral reflux. J Urol. Jan 2000;163(1):269-72; discussion 272-3. [Medline].
  11. Dewan PA, Hoebeke P, E Hall H. Migration of particulate silicone after ureteric injection with silicone. BJU Int. Apr 2000;85(4):557-557.
  12. Feather SA, Malcolm S, Woolf AS, Wright V, Blaydon D, Reid CJ. Primary, nonsyndromic vesicoureteric reflux and its nephropathy is genetically heterogeneous, with a locus on chromosome 1. Am J Hum Genet. Apr 2000;66(4):1420-5. [Medline].
  13. Greenfield SP, Ng M, Wan J. Resolution rates of low grade vesicoureteral reflux stratified by patient age at presentation. J Urol. Apr 1997;157(4):1410-3. [Medline].
  14. Hansson S, Dhamey M, Sigström O, Sixt R, Stokland E, Wennerström M. Dimercapto-succinic acid scintigraphy instead of voiding cystourethrography for infants with urinary tract infection. J Urol. Sep 2004;172(3):1071-3; discussion 1073-4. [Medline].
  15. Hellstrom M, Jacobsson B. Diagnosis of vesico-ureteric reflux. Acta Paediatr Suppl. Nov 1999;88(431):3-12. [Medline].
  16. Information from your family doctor. Urinary reflux. Am Fam Physician. Jan 1 2004;69(1):152. [Medline].
  17. Jacobson SH, Hansson S, Jakobsson B. Vesico-ureteric reflux: occurrence and long-term risks. Acta Paediatr Suppl. Nov 1999;88(431):22-30. [Medline].
  18. Jodal U, Hansson S, Hjalmas K. Medical or surgical management for children with vesico-ureteric reflux?. Acta Paediatr Suppl. Nov 1999;88(431):53-61. [Medline].
  19. Jodal U, Koskimies O, Hanson E. Infection pattern in children with vesicoureteral reflux randomly allocated to operation or long-term antibacterial prophylaxis. The International Reflux Study in Children. J Urol. Nov 1992;148(5 Pt 2):1650-2. [Medline].
  20. Liu C, Chin T, Wei C. Contralateral reflux after unilateral ureteral reimplantation--preexistent rather than new-onset reflux. J Pediatr Surg. Nov 1999;34(11):1661-4. [Medline].
  21. Marra G, Oppezzo C, Ardissino G, Daccò V, Testa S, Avolio L. Severe vesicoureteral reflux and chronic renal failure: a condition peculiar to male gender? Data from the ItalKid Project. J Pediatr. May 2004;144(5):677-81. [Medline].
  22. Mingin GC, Nguyen HT, Baskin LS, Harlan S. Abnormal dimercapto-succinic acid scans predict an increased risk of breakthrough infection in children with vesicoureteral reflux. J Urol. Sep 2004;172(3):1075-7; discussion 1077. [Medline].
  23. Nguyen HT, Bauer SB, Peters CA, Connolly LP, Gobet R, Borer JG. 99m Technetium dimercapto-succinic acid renal scintigraphy abnormalities in infants with sterile high grade vesicoureteral reflux. J Urol. Nov 2000;164(5):1674-8; discussion 1678-9. [Medline].
  24. Park J, Retik AB. Surgery for vesicoureteral reflux. Ped Urol. 2001;421-429.
  25. Polito C, Moggio G, La Manna A. Cyclic voiding cystourethrography in the diagnosis of occult vesicoureteric reflux. Pediatr Nephrol. Ja